- Home
- TCRT vs BPTH Comparison
TCRT vs BPTH Comparison
Compare TCRT & BPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- BPTH
- Stock Information
- Founded
- TCRT 1998
- BPTH 2007
- Country
- TCRT United States
- BPTH United States
- Employees
- TCRT N/A
- BPTH N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- BPTH Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- BPTH Health Care
- Exchange
- TCRT Nasdaq
- BPTH Nasdaq
- Market Cap
- TCRT 3.2M
- BPTH 3.5M
- IPO Year
- TCRT N/A
- BPTH N/A
- Fundamental
- Price
- TCRT $1.80
- BPTH $0.82
- Analyst Decision
- TCRT
- BPTH Strong Buy
- Analyst Count
- TCRT 0
- BPTH 2
- Target Price
- TCRT N/A
- BPTH $30.00
- AVG Volume (30 Days)
- TCRT 25.3K
- BPTH 6.3M
- Earning Date
- TCRT 11-14-2024
- BPTH 03-07-2025
- Dividend Yield
- TCRT N/A
- BPTH N/A
- EPS Growth
- TCRT N/A
- BPTH N/A
- EPS
- TCRT N/A
- BPTH N/A
- Revenue
- TCRT $7,000.00
- BPTH N/A
- Revenue This Year
- TCRT N/A
- BPTH N/A
- Revenue Next Year
- TCRT N/A
- BPTH N/A
- P/E Ratio
- TCRT N/A
- BPTH N/A
- Revenue Growth
- TCRT N/A
- BPTH N/A
- 52 Week Low
- TCRT $1.63
- BPTH $0.59
- 52 Week High
- TCRT $33.00
- BPTH $10.00
- Technical
- Relative Strength Index (RSI)
- TCRT 44.52
- BPTH 42.72
- Support Level
- TCRT $1.67
- BPTH $0.69
- Resistance Level
- TCRT $1.87
- BPTH $1.22
- Average True Range (ATR)
- TCRT 0.15
- BPTH 0.13
- MACD
- TCRT -0.00
- BPTH -0.04
- Stochastic Oscillator
- TCRT 22.41
- BPTH 20.00
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.